Abstract
Survival after invasive bladder cancer has improved less than that of other common non-skin cancers. In many types of malignancy, treatment failure has been attributed to therapy-resistant stem-like cancer cells. Our aim was therefore to determine identities of stem cell marker-positive cells in bladder cancer tissue and to investigate possible associations between these cells and different forms of bladder neoplasia. We investigated tissue from 52 patients with bladder neoplasia and 18 patients with benign bladder conditions, from a cohort that had been previously described with regard to diagnosis and outcome. The samples were analysed immunohistologically for the stem cell markers aldehyde dehydrogenase 1 A1 (ALDH1) and CD44, and markers of cell differentiation. The majority of stem cell marker-positive cells were located in connective tissue, and a smaller fraction in epithelial tissue. Stem cell marker-positive cells exhibiting possible stem cell characteristics included cells in deeper locations of benign and malignant epithelium, and sub-endothelial cells in patients with or without neoplasia. Stem cell marker-positive cells with non-stem cell character included stellate cells, mast cells, endothelial cells, foamy histiocytes, and neurons. Significantly, ALDH1+ stellate cells and ALDH1+ mast cells were reduced in number in stroma of benign-appearing mucosa of bladder cancer patients. The stem cell markers ALDH1 and CD44 label several types of differentiated cells in bladder tissue. ALDH1+ stellate cells and mast cells appear to be reduced in stroma of normal-appearing mucosa of bladder cancer patients, and may be part of a “field effect” in cancer-near areas.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Among the five most common forms of non-skin malignant disease, bladder cancer is the one for which least improvement has been achieved with regard to patient outcome during the last three decades, at the same time as it is the most expensive cancer to manage on patient basis [1–4]. The most common histological type of bladder cancer is urothelial [5]. Its flat, high-grade, pre-invasive form (carcinoma in situ, CIS) occurs concomitantly with visible tumours in up to 50 % of bladder cancer patients [6–10]. In fact, the majority of invasive bladder cancer foci originate in CIS, and up to 45 % of patients with CIS progress to invasive disease and die within 10 years [8–19]. The patient material in this study was selected from all bladder specimens collected during 24 consecutive months of care at the urology services in Telemark County, Norway (pop. ∼170,000), hence population-based [10].
Adult somatic stem cells (SCs) are characterised by their ability to renew tissues and generate different types of terminally differentiated cells [20, 21]. Cancer-associated SCs (CSCs) (alternative and perhaps more appropriate term: stem-like cancer cells), that were first documented in malignancies of haematopoietic tissue, colon, and breast [22–24], are interesting for the fact that in breast they are resistant to chemotherapy and cause late recurrences [21]. The combined immunophenotype CD44+ CD24−/low Lineage−/low was the first cellular protein SC marker (SCM) identified for epithelial cells, and aldehyde dehydrogenase 1 A1 (ALDH1) was the first single SCM (thus especially practical for immunohistochemistry (IHC) purposes) [24, 25]. ALDH1 labels a subpopulation of CD44+ cells in epithelial organs, including breast, pancreas, colon, prostate, and urinary bladder, and the combined ALDH1+ CD44+ immunophenotype appears to be particularly potent for identifying stem cells [24, 26–29]. With regard to the comparative efficiency of these markers, the outcome of chemotherapy is better predicted by the tumoural presence of ALDH1+ cells than CD44+ CD24− cells [30]. Considering the urinary bladder, in situ evidence of SCs or CSCs has been lacking in benign tissue, in CIS, and in the stroma of invasive cancer [29]. Most experimental studies have required a population of approximately 100–1,000 SCM+ cells to consistently elicit SC functions, which indicates that the majority of SCM+ cells are indeed not SCs. Accordingly, the present study aimed to establish possible differentiated identities of SCM-positive cells.
ALDH1 is not only a SCM but it is also vital for vitamin A (retinoid) metabolism. Retinoids are essential for cell differentiation and for detoxification of endogenous and exogenous substances [31]. In the intestine, vitamin A is taken up as retinyl esters that are subsequently stored in hepatic stellate cells. The early vitamin A metabolite retinol is formed in hepatocytes and then delivered to retinol-binding proteins in the circulation. Retinol is taken up by extra-hepatic stellate cells, in which it is bound by cellular retinol-binding protein 1 (CRBP1). The aldehyde dehydrogenase 1 family of enzymes transform retinol into the metabolically most active form of retinoid, retinoic acid. Within cells, retinoic acid is bound to cellular retinoic acid-binding protein type 1 (CRABP1), which is expressed in most types of human cells [32]. ALDH1 eliminates aldehydes, which are cytotoxic, and it also aids the removal of chemotherapeutic agents, the latter capacity representing one of the mechanisms that render ALDH1+ SCs resistant to chemotherapy [30]. Thus, the roles of aldehyde dehydrogenases as SCMs and as essential enzymes in retinoid metabolism and chemotherapy resistance may be interrelated through mechanisms of cell differentiation and cell preservation. Therefore, we conducted the current study to examine the concomitant presence of the major retinoid-binding proteins and ALDH1 in cells in the lamina propria of urinary bladder with and without neoplasia.
In light of recent evidence of the importance of the microenvironment in cancer, it is possible that the management of bladder cancer would be improved by increased understanding of cells in the microenvironment, including SCs. We hypothesised that SCM+ cells would exhibit abnormal distribution in bladder cancer tissue.
Materials and methods
Patients
In this retrospective study, the patient material was obtained from our previously published studies of 272 consecutive bladder tissue samples that had been re-diagnosed by uropathologist consensus according to the 2004 World Health Organization classification of neoplasia [10, 33–35]. The material was population-based. All patients with any of the following bladder conditions were included, as defined by the above-mentioned classification: dysplasia, CIS, invasive carcinoma, and non-neoplastic disease. Only specimens with unequivocal diagnoses were considered, and if more than one specimen had been obtained from a patient the earliest specimen was selected. Seventy patients were included in the investigation: 52 had neoplasia, and 23 of those subjects were under follow-up for non-muscle-invasive bladder cancer; the remaining 18 patients had no evidence of neoplasia in the current or previous specimens, or within the follow-up period of a minimum of 35 months [33]. In the neoplastic groups, 26 patients (50 %) had CIS, and all of those individuals were found to have a high-grade papillary or invasive urothelial tumour in the current or a previous specimen. The median age was 76 years among the patients with neoplasia but 56 years for those with non-neoplastic conditions (see Table 1).
Biological material and immunohistochemistry
Formalin-fixed paraffin-embedded tissue was used for analysis. From each specimen, one tissue block was selected according to the features upon which the consensus diagnosis had been made, and it was sectioned for histological staining and immunohistochemistry (IHC) as described previously [10, 33].
ALDH1 IHC was performed as single-antibody reactions for all selected tissue material. Double IHC using ALDH1 combined with CD44, with CRABP1, or with CRBP1 was performed on six randomly selected specimens from each of these three patient categories: CIS, invasive tumour, and benign. To determine cell differentiation in selected cases, single- and double-antibody reactions were carried out using S-100, CD68, cytokeratin AE1/AE3, vimentin, and CD117. Single-antibody reactions were conducted in a Dako Autostainer with PT Link (Dako Denmark A/S, Glostrup, Denmark) according to the manufacturer’s instructions. Double-antibody reactions were done using a Benchmark XT system (Ventana Medical Systems, Inc., Tucson, Arizona, USA). For double reactions, ALDH1 was labelled red with an UltraView Universal Alkaline Phosphatase Red Detection Kit, and the other antibody was labelled brown with an UltraView DAB Detection Kit (both from Ventana Medical Systems Inc.). Alcian blue staining was performed in a standard fashion at pH 0.5 to visualise mast cells. The antibodies and IHC conditions applied are listed in Table 2.
Microscopy
Two pathologists (BLI and CB) examined haematoxylin and eosin (H&E) and IHC tissue sections primarily in a Nikon Eclipse Ni microscope (Nikon Instruments Europe BV, Amsterdam, the Netherlands). Histological and IHC findings were photographed using a Nikon Digital Sight DS-Fi2 camera and NIS Elements 4.00.00 imaging software (Nikon). IHC results for each specimen were recorded simply as the presence or absence of positive (or double positive) cells, for each morphological cell type and location. For stromal findings, only observations from the soft tissue between the epithelium and muscularis propria were included.
Statistical analysis
Comparisons between groups were performed using the fraction of specimens that contained any positive cells for the relevant marker(s) in each group. Fisher’s exact test of probability was used to evaluate associations, and p < 0.05 (two-tailed) was considered to be statistically significant. For some statistical analyses, the total study population was divided into age groups as indicated in the text below.
Ethics
The regional ethics committee (REK sør-øst) approved the study plan (2012/1730/REK sør-øst A), and waived need for informing patients or obtaining patient consent. The study included consecutive hospital patients not selected for gender, race, or age. The authors declare no conflicts of interest.
Results
ALDH1+ cell morphology by location
Within benign urothelium and squamous epithelium (bladder trigonum), most ALDH1+ cells were of epithelial type, confluent and integrated into the architecture (Fig. 1a–e). Epithelial-type ALDH1+ cells were also observed in urothelial carcinoma cell sheets (Fig. 2a–f). Less often, in both benign and malignant tissue, ALDH1+ cells in epithelium occurred as single cells that were morphologically indistinguishable from adjoining cells (Fig. 2g–h). Most ALDH1+ cells were however located in the stroma (Fig. 2i–k). Scattered invasive tumour areas contained ALDH1+ cells that resembled foamy macrophages and were located in the stroma; these cells were positive for CD68 (Fig. 3a–c). In the lamina propria of neoplastic and non-neoplastic tissue, the most common type of ALDH1+ cells had a spindle-shaped or angular cell body and cytoplasmic extensions, and the cytoplasm was positive for ALDH1 and often contained small vacuoles. Many of these ALDH1+ cells were also CRBP1 positive (see below), and ALDH1− CRBP1+ cells with the same morphology were observed as well (Fig. 4a–l). The second most common ALDH1+ cell variant in the stroma was mononuclear leukocyte-like, round or oval, with a small regular nucleus and cytoplasm with a granular appearance that was recapitulated in granular ALDH1 positivity; these cells were positive for CD117 (c-kit) and Alcian blue staining performed at pH 0.5 (Fig. 5a–h). A less common location for ALDH1+ cells in stroma was underneath the endothelium of occasional capillaries (Fig. 6a–b). Also, endothelial cells in sporadic capillaries were ALDH1+ (Fig. 7a–b). Furthermore, all nerves in benign and malignant specimens were consistently positive for ALDH1, CD44, and S-100 (Fig. 8a–d).
Histologically benign tissue in cancer versus non-cancer patients
Table 3 outlines the distribution and morphology of ALDH1+ cells in histologically benign mucosal areas in bladder tissue from patients with and without bladder cancer. Only 19 of 52 patients with neoplasia had such tissue represented in their specimen; this lack of benign urothelium in tumour resection material has been commented on before [10]. Confluent ALDH1+ epithelial cells were detected in benign-appearing urothelium in 74 % of cancer patients and 39 % of non-cancer patients (p = 0.049). However, the presence of these cells was more closely associated with patients being below median age (p = 0.018), and no statistically significant associations were found between ALDH1+ cells and cancer status in separately analysed age groups. ALDH1+ mast cells were detected in the lamina propria of benign-appearing urothelium in 47 % of bladder cancer patients and 100 % of non-cancer patients (p = 0.023), and when this association was analysed separately for patients being below or above median age, it remained statistically significant for low age (p = 0.032). Similarly, ALDH1+ stellate cells were detected in the lamina propria of benign-appearing urothelium in 53 % of patients with bladder cancer and 94 % of those without such disease (p = 0.008), and no significant association with age was found for this variable. Patients with CIS lacked ALDH+ stellate cells underneath normal epithelium in 7/11 (64 %) cases, compared with 2/8 (25 %) cases for non-neoplastic patients, although this difference was not statistically significant.
Neoplastic tissue
Results regarding ALDH1 in neoplastic bladder tissue are given in Table 4. In neoplastic urothelium, ALDH1+ cells were present in a similar proportion of dysplastic and CIS lesions, and in slightly higher numbers in invasive cancer lesions, but none of these levels were significantly different internally or from what was observed in urothelium of non-cancer patients. Notwithstanding, in invasive tumour areas, ALDH1+ cells were found much more frequently in the stroma than in the tumour cell sheets (Fig. 2i–k). In the lamina propria, ALDH1+ mast cells and ALDH1+ stellate cells were present in almost all neoplastic and non-neoplastic specimens. No trends or significant differences were found for different grades or stages of neoplasia or all neoplasia compared with specimens from non-cancer patients, and the same was noted for all the different types of ALDH1+ cells and locations that were analysed.
CD44+ cells
In benign urothelium, cytoplasmic CD44 positivity with accentuated membranous positivity was observed in basally and intermediately located cells, whereas umbrella cells were generally negative for CD44. Meanwhile, glycogen-rich urothelial and squamous cells were strongly CD44+. Tumour cell sheets were at least focally CD44+ in the great majority of tested specimens, and this cell positivity tended to be in a basal location (i.e., near the stroma). In CIS urothelium, there was CD44 positivity at least basally in most cases. In both benign and malignant tissue, double IHC analysis against ALDH1 and CD44 revealed that essentially all cell types addressed in this study occurred with all possible permutations of positivity for these two protein epitopes, except that neurons occurred only as ALDH1+ CD44+. For the ALDH1+ CD44+ immunophenotypes, no statistically significant differences were found between benign and malignant tissue specimens (see Table 5).
CRBP1+ cells
CRBP1 positivity in urothelium, although present in the majority of cases, occurred only focally and was very weak in both malignant and benign specimens. Differently, in the lamina propria, CRBP1 positivity and CRBP1−ALDH1 co-positivity were widespread and was observed in the following cell types in neoplasia- and non-neoplasia patients: stellate cells (primarily immunophenotype ALDH1+ CRBP1+), mast cells (mostly ALDH1+ CRBP1+ and ALDH1−CRBP1+), and endothelial cells (chiefly immunophenotype ALDH1+ CRBP1+). Statistically significant differences between benign and malignant specimens were noted for CRBP1+ mast cells in the lamina propria, which occurred less frequently in malignant specimens than in benign specimens (p = 0.009; see Table 5).
CRABP1+ cells
Confluent areas of CRABP1+ epithelial cells were present in all specimens (see Fig. 9a–d). The general impression was that even more extensive CRABP1 positivity was present in malignant urothelium than in benign urothelium (not quantified). For the lamina propria, specimens showed weak and focal CRABP1 positivity for the following cell types in both benign and malignant tissue: stellate cells, mast cells, and endothelial cells. There were no significant differences regarding the frequency of CRABP1+ or ALDH1+ CRABP1+ cells in malignant tissue as compared to benign specimens (see Table 5).
Discussion
In the neoplastic epithelium, only one ALDH1+ cell type was identified: epithelial. The frequency of this cell type in neoplastic epithelium did not differ significantly from benign epithelium. Differently, sub-epithelial stroma of neoplastic lesions exhibited significant reduction in the frequencies of ALDH1+ stellate cells and ALDH1+ mast cells. This suggests that future stem cell marker studies should focus on the stroma rather than the lesion as a whole.
A large number of cell types addressed in this study exhibited all possible variations of positivity for ALDH1 and CD44 in double IHC analysis, which is in itself consistent with earlier studies showing that both of these markers can serve as SCMs, especially when they are present simultaneously. Notwithstanding, a number of cell types that were positive for both these markers did show features of specific non-stem cells. For example, the CD44+ and ALDH1+ spindle- or stellate-shaped cells exhibited small intracytoplasmic vacuoles and were positive for CRBP1, characteristics that concur with the morphological appearance and the retinoid transport role of previously described stellate cells. The CD44+ and ALDH1+ round/oval leukocyte cell type was positive for CD117 and Alcian blue staining at pH 0.5, consistent with mast cells. The CD44+ and ALDH1+ cytoplasm-rich foamy cells were also positive for CD68, thus identified as histiocytes. Neurons were consistently CD44+/ALDH1+, and also endothelial cells of some capillaries showed such positivity. Together, these constitute the five types of SMC+ cells that were identified as differentiated cells in this study.
With regard to benign and malignant urothelium, single and confluent CD44+ ALDH1+ cells were detected predominantly in basal/near-basal or tumour front locations, thus suggesting that some of those may be urothelial SCs [36]. Sub-endothelially located cells with a CD44+ and/or ALDH1+ phenotype had a distribution that suggests pericytes, but, based on recent data indicating that sub-endothelial or peri-vascular sites are preferential locations for SCs [37], it is possible that they are instead SCs. We perceived these two types of CD44+ ALDH1+ cells, deeply located epithelial cells and sub-endothelial cells, as being consistent with SCs.
ALDH1+ mast cells occurred in abnormally low numbers in the lamina propria of benign-appearing urothelium of the patients with bladder cancer, which, when considering the multifocal and recurrent nature of bladder cancer (implying field effect), suggests that ALDH1+ mast cells may play a protective role against cancer. This is congruent with earlier data that the presence of mast cells is reduced in tissue of various cancers, as described below. Also, CRBP1+ mast cells in the lamina propria occurred less commonly in malignant specimens compared with specimens from non-cancer patients, this novel finding also supporting the idea that mast cells play a cancer-preventive role. Similar to the present study, other investigations have shown that SCs in myocardium include CD117 positive mast cells [38, 39]. Our results suggest an inverse relationship between SCM+ mast cells and cancer, which supports earlier reports concerning the low occurrence of mast cells in cancers of the uterine cervix, breast, colon, prostate, and lung [40–44].
With an even higher level of statistical significance, the number of ALDH1+ stellate cells in the lamina propria of benign-appearing urothelium was abnormally low in patients with bladder cancer, which suggests that also ALDH1+ stellate cells are involved in suppression of carcinogenesis. As a supplement to our investigation in relation to the identity of stellate cells, we also performed experiments focused on CRABP1. As expected, we found strong positivity for CRABP1 in cancerous urothelium, tissue that can be assumed to be a significant “end-user” of retinoic acid. By comparison, cellular expression of this protein was lower in benign urothelium. In the present material, stellate cells were in fact the most common SCM+ cell type in superficial layers of benign bladder tissue. The scientist von Kupffer discovered stellate cells in 1876 and called them Stern-Zellen, and his pupil Rothe later reported observing small cytoplasmic vacuoles in the same cells [45, 46]. Stellate cells have been referred to by different names, such as vitamin A-storing cells and Ito cells [47–53]. In 1963, it was shown that the cytoplasmic vacuoles contain retinoids [54]. Stellate cells have been identified in most organs, including the urinary bladder [55, 56], and are strongly positive for smooth muscle actin in their cytoplasm [57]. Stellate cells are major providers of retinoic acid for other cells. Thus, although the reduced presence of stellate cells in the benign-appearing bladder mucosa of cancer patients has not yet been explained, it can be suggested that a decrease in the numbers of such cells diminishes the supply of retinoic acid and thereby increases the susceptibility to carcinogenesis.
ALDH1+ cells were much more numerous in the stroma than within the carcinomatous epithelium. This observation is noteworthy, because the presence of ALDH1+ putative stem or stem-like cells in bladder cancer tissue has previously been described without any detailed specification of the histological location of these cells [29]. In our study, ALDH1+ cells were found in similar numbers in dysplastic and CIS lesions, and were somewhat more common in invasive cancer lesions, but this did not differ significantly from what we observed in benign tissue from non-cancer patients. The lack of statistically significant differences between carcinoma tissue and tissue from non-cancer patients is difficult to explain, in light of the fact that the frequency of certain SCM+ cells was significantly decreased in normal-appearing mucosa of bladder cancer patients. We can offer a possible explanation that the microenvironment of cancerous tissue is radically altered with respect to cell composition, intercellular matrix, and metabolism, which may cause multiple factors to influence the occurrence of SCM+ cells, making it difficult to isolate individual factors [58]. Perhaps surprisingly, CIS tissue showed no statistically significant associations with regard to any examined immunophenotypes; hence, this must be investigated in a larger set of specimens.
With regard to aldehyde dehydrogenases as SC markers, a case can be made that retinoic acid is necessary for the initiation of differentiation, and that it contributes to cell preservation and resistance to toxic substances; qualities that are important for long-term quiescent cells that “await the call of duty” to generate differentiated cell progenies. Due to the abundance of evidence indicating that aldehyde dehydrogenase 1 A1 was the most efficient established epithelial organ stem cell marker to date, this was selected as the principal stem cell marker.
To some degree, sectioning of tissue blocks resulted in a shift of distinctive structures between near-consecutive slides. Therefore, we used double IHC to demonstrate cellular co-presence of markers, and we also ensured antibody specificity by employing monoclonal antibodies, and purified polyclonal antibodies that have been characterised extensively in human tissues. This study was essentially qualitative in nature, including a large number of observed features, and hence quantification was kept as simple as possible: presence or absence of the relevant cell type in each specimen. Image analysis was not used, because such evaluation depends on guidance of the investigator and is thus prone to subjectivity. Combined staining for two antibodies was done on only a sub-set of the entire material, which may have reduced the statistical power of the evaluation and consequently given a false impression of non-significant results for some of the features that were examined. Also, it should be kept in mind that the majority of benign-appearing mucosal areas examined in this study were derived from tumour resection specimens, raising possibilities that the frequencies of stromal cells could be directly influenced by the close proximity to tumour.
By means of IHC, our study identified several types of SCM+ differentiated cells in the microenvironment of benign and malignant urinary bladder mucosa. Meanwhile, it must be borne in mind that SCs are defined through functional studies in vivo that identify cell populations characterised by longevity, pluripotency, and tumour initiation. Such investigations have pinpointed protein cell markers that enrich mixed cell populations for SCs. The markers can be used in IHC studies to label cells in situ and thereby histologically visualise cell populations that include SCs. To date, this results in cell populations that contain only about 1 functional SC in 100 to 1,000 SCM+ cells. The results of our study demonstrate that non-specificity is a major explanation for the low efficiency of SCMs, which encourages the search for more specific epithelial SC markers.
Conclusion
Whereas previous studies have firmly established ALDH1 and CD44 as useful markers for SCs, the present results show that these markers also label several types of differentiated cells, including stellate cells and mast cells. Both of these two cell types were significantly reduced in number in the microenvironment of benign-appearing bladder epithelium in patients with bladder cancer, suggesting that this may be a part of a field effect that causes tumour multifocality and recurrence, and that these particular cells may play a tumour-suppressive role.
References
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Cancer in Norway 2011: Cancer incidence, mortality, survival and prevalence in Norway (2013) Cancer Registry of Norway, Institute of Population-based Cancer Research. http://kreftregisteret.no/Global/Cancer%20in%20Norway/2011/cin2011_with_special_issue-NORDCAN.pdf. Accessed 17 October 2013
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer. A comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330
Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 92:241–245
Young RH (2008) Non-neoplastic disorders of the urinary bladder. Histology. In: Bostwick DG, Cheng L (ed) In: Urologic Surgical Pathology, 2nd edn. Elsevier, pp 217-219
Isfoss BL (2011) The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int 108:1703–1707
Althausen AF, Prout GR, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116:575–580
Soto EA, Friedell GH, Tiltman AJ (1997) Bladder cancer as seen in giant histologic sections. Cancer 39:447–455
Koss LG, Nakanishi I, Freed SZ (1977) Nonpapillary carcinoma in situ and atypical hyperplasia in cancerous bladders. Further studies of surgically removed bladders by mapping. Urology 9:442–455
Isfoss BL, Majak B, Busch C, Braathen GJ (2011) Diagnosis of intraurothelial neoplasia. Interobserver variation and the value of individual histopathologic attributes. Anal Quant Cytol Histol 33:75–81
Sylvester RJ, van der Mejden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477
Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts BE, Bostwick DG (1999) Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85:2469–2479
Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH et al (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74–80
Cooper PH, Waisman J, Johnston WH, Skinner DG (1973) Severe atypia of transitional epithelium and carcinoma of the urinary bladder. Cancer 31:1055–1060
Koss LG, Tiamson EM, Robbins MA (1974) Mapping cancerous and precancerous bladder changes. JAMA 227:281–286
Farrow GM, Utz DC, Rife CC (1976) Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res 36:2495–2501
Farrow GM, Utz DC, Rife CC, Greene L (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 27:2794–2798
Koss LG (1979) Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum Pathol 10:533–548
Brawn PN (1982) The origin of invasive carcinoma of the bladder. Cancer 50:515–519
Clarke MF, Dick JE, Dirks PB, Eaves CH, Jamieson CHM, Jones DL et al (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344
Gupta PB, Chaffer CI, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15:1010–2012
Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al (2004) Characterization of clonigenic multiple myeloma cells. Blood 103:2332–2336
OBrien CA, Pollett A, Gallinger S, Dick JE (2006) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 15:555–567
Al-Hajj WMS, Benito-Hernandez MSJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. PNAS 100:3983–3988
Rovira M, Scott SG, Liss AS, Jensen J, Thayer SP, Leach SD (2009) Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci U S A 107:75–80
Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389
Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D, Wilson EL (2009) High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 27:220–2228
Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z et al (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19:327–337
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Tagutchi T (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241
Duester G (2008) Retinoid acid synthesis and signaling during early organogenesis. Cell 134:921–931
The Human Protein Atlas (2013) CRABP1. The Swedish Human Protein Atlas Project. http://proteinatlas.org/ENSG00000166426. Accessed 17 Oct 2013
Isfoss BL, Majak B, Busch C, Braathen GJ (2011) Diagnosis of intraurothelial neoplasia. Interobserver variation and the value of individual histopathologic attributes. Anal Quant Cytol Histol 33:75–81
Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol 22:1435–1448
Tumours of the urinary system (2004) In: Eble JN, Sauter G, Epstein JI and Sesterhenn IA (ed) WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARCPress, Lyon, pp 89–157
van der Horst G, Bos L, van der Pluijm G (2012) Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 10:995–1009
Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301–313
Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S et al (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114:763–776
Zhou Y, Pan P, Yao L, Meng S, Ping H, Niu N et al (2010) CD117-positive cells of the heart: progenitor cells or mast cells? J Histochem Cytochem 58:309–316
Jain PC, Singh SN, Pratap VK, Lahiri B (1977) Connective tissue changes and mast cell variations in benign and malignant lesions of the uterine cervix. Int Surg 62:358–360
Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C et al (2004) The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17:690–695
Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F (1999) Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 189:487–495
Fleischmann A, Schlomm T, Köllermann T, Sekulic N, Huland H, Mirlacher M et al (2009) Immunological microenvironment in prostate cancer. High mast cell densities are associated with favourable tumor characteristics and good prognosis. Prostate 69:976–981
Carlini MJ, Dalurzo MC, Lastiri JM, Smith DE, Vasallo BC, Puricelli LI, Lauría de Cidre LS (2010) Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 41:697–705
Norum KR (1984) The name of the perisinusoidal stellate cells, fat-storing cells, pericytes, vitamin A-storing cells of the liver. Kupffer Cell Bull 5:13
Wake K (1971) "Sternzellen" in the liver: Perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 132:429–461
Berkley HJ (1893) Studies in the histology of the liver. III. The perivascular cells of the rabbits liver. Anat Anz 8:787–792
Zimmerman KW (1923) Der feinere bau der blutkapillären. Z Anat 68:29–109
Ito T (1951) Cytological studies on stellate cells of Kupffer and fat-storing cells in the capillary wall of the human liver. Acta Anat Nippon 26:2
Suzuki K (1958) A silver impregnation method in histology. Takeda Pharm Ind Ozaka 310–320
Bronfenmajer S, Schaffer F, Popper H (1966) Fat storing cells (lipocytes) in human liver. Arch Pathol 82:447–553
Yamada E, Hirosawa K (1976) The possible existence of a vitamin A-storing cell system. Cell Struct Funct 1:201–204
Hruban Z, Russell RM, Boyer JL, Glagov S, Bagheri SA (1974) Ultrastructural changes in livers of two patients with hypervitaminosis A. Am J Pathol 76:451–468
Nakane PK (1963) Ito’s "fat-storing cell" of the mouse liver. Anat Rec 145:265–266
Wake K (1980) Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int Rev Cytol 66:303–353
Nordlinder H, Eriksson U, Busch C (1991) Identification of extrahepatic stellate cells and the cell specific regulation of cellular retinol binding protein. Dissertation, Uppsala University. Acta Universitatis Upsaliensis nr. 284, paper 5
Nagy NE, Holven KB, Roos N, Senoo H, Kojima N, Norum KR, Blomhoff R (1997) Storage of vitamin A in extrahepatic cells in normal rats. J Lipid Res 38:645–658
Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A (2010) Understanding the "lethal" drivers of tumor-stroma co-evolution. Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment. Cancer Biol Ther 10:537–542
Acknowledgments
This study was financed by the Telemark Hospital Research and Development Fund. We thank Linda Røland Svensson at Telemark Hospital and Ulla Larsson Petterson at Akademiska Sjukhuset Uppsala for laboratory assistance, and ImaGene-iT AB in Sweden for image processing and figure compilation.
Acknowledgment of funding and grants
R&D Fund, Telemark Hospital, 3710 Skien, Norway
Disclosure of Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Isfoss, B.L., Busch, C., Hermelin, H. et al. Stem cell marker-positive stellate cells and mast cells are reduced in benign-appearing bladder tissue in patients with urothelial carcinoma. Virchows Arch 464, 473–488 (2014). https://doi.org/10.1007/s00428-014-1561-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-014-1561-2